Literature DB >> 14574513

11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.

Kotaro Higashi1, Yoshimichi Ueda, Ichiro Matsunari, Yuko Kodama, Ryosuke Ikeda, Katsuyuki Miura, Suzuka Taki, Takahiro Higuchi, Hisao Tonami, Itaru Yamamoto.   

Abstract

Recently carbon-11 acetate (AC) positron emission tomography (PET) has been reported to be of clinical value for the diagnosis of cancer that is negative on fluorine-18 fluorodeoxyglucoce (FDG) PET. We investigated the uptake of AC in lung cancer to determine whether this tracer is of potential value for tumour detection and characterisation, and to compare AC PET imaging with FDG PET and technetium-99m sestamibi (MIBI) single-photon emission tomography (SPET). Twenty-three patients with 25 lung cancers underwent AC and FDG PET. Twenty of 23 patients were also investigated with MIBI SPET. Dynamic images were acquired for 26 min after the injection of 555 MBq of AC. Standardised uptake values (SUVs) and/or tumour to non-tumour activity ratios (T/N) for each tumour were investigated at 10-20 min after AC administration, 40-60 min after administration of 185 MBq FDG and 15-45 min after administration of 555 MBq MIBI. Twenty lung cancers were resected surgically, and the degree of tracer uptake in the primary lesion was correlated with histopathological features (cell dedifferentiation and aggressiveness) and prognosis. Rapid uptake of AC followed by extremely slow clearance was observed. For the purpose of tumour identification, AC PET was inferior to FDG PET in 8 of 25 (32%) lung cancers, and the T/N of AC was lower than that of FDG. However, AC PET was superior to FDG PET in the identification of a slow-growing tumour (bronchiolo-alveolar carcinoma). There was a positive correlation between AC uptake (T/N) and MIBI uptake (T/N) (r=0.799, P<0.0001). A positive correlation was not observed between either AC or MIBI uptake and the degree of cell dedifferentiation in lung adenocarcinomas, whereas FDG uptake did correlate with the degree of cell dedifferentiation. In lung adenocarcinoma, there was a weak correlation between aggressiveness and FDG uptake, but no correlation was evident for AC and MIBI. In addition, a positive correlation was not observed between AC or MIBI uptake and postoperative recurrence in lung adenocarcinoma, whereas FDG uptake did correlate with postoperative recurrence. Thus, the greater the FDG uptake, the higher the malignant grade. In conclusion, for the purpose of tumour identification, AC PET was inferior to FDG PET but superior to MIBI SPET. Neither AC nor MIBI uptake reflects the malignant grade in lung adenocarcinoma, whereas FDG uptake does. AC PET is less diagnostically informative than FDG PET in patients with lung cancer. However, AC PET may play a complementary role in the identification of low-grade malignancies that are not FDG avid.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14574513     DOI: 10.1007/s00259-003-1326-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  22 in total

1.  11C-acetate clearance in nasopharyngeal carcinoma.

Authors:  S H Yeh; R S Liu; L C Wu; S H Yen; C W Chang; K Y Chen
Journal:  Nucl Med Commun       Date:  1999-02       Impact factor: 1.690

2.  Imaging of the pancreas and related diseases with PET carbon-11-acetate.

Authors:  P D Shreve; M D Gross
Journal:  J Nucl Med       Date:  1997-08       Impact factor: 10.057

3.  31. Clinical Application of

Authors: 
Journal:  Clin Positron Imaging       Date:  2000-07

4.  FDG PET measurement of the proliferative potential of non-small cell lung cancer.

Authors:  K Higashi; Y Ueda; M Yagishita; Y Arisaka; A Sakurai; M Oguchi; H Seki; Y Nambu; H Tonami; I Yamamoto
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

5.  Evaluation of primary pulmonary carcinoid tumors using FDG PET.

Authors:  J J Erasmus; H P McAdams; E F Patz; R E Coleman; V Ahuja; P C Goodman
Journal:  AJR Am J Roentgenol       Date:  1998-05       Impact factor: 3.959

6.  MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model.

Authors:  Nobuyuki Oyama; Joonyoung Kim; Lynne A Jones; Nicole M Mercer; John A Engelbach; Terry L Sharp; Michael J Welch
Journal:  Nucl Med Biol       Date:  2002-11       Impact factor: 2.408

7.  FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features.

Authors:  K Higashi; Y Ueda; K Ayabe; A Sakurai; H Seki; Y Nambu; M Oguchi; H Shikata; S Taki; H Tonami; S Katsuda; I Yamamoto
Journal:  Nucl Med Commun       Date:  2000-08       Impact factor: 1.690

8.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.

Authors:  Chi-Lai Ho; Simon C H Yu; David W C Yeung
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

9.  Tc-99m MIBI scintigraphy in patients with lung cancer. Comparison with CT and fluorine-18 FDG PET imaging.

Authors:  H Wang; S Maurea; C Mainolfi; F Fiore; A Gravina; M R Panico; L Bazzicalupo; M Salvatore
Journal:  Clin Nucl Med       Date:  1997-04       Impact factor: 7.794

10.  Carbon-11-acetate PET imaging in renal disease.

Authors:  P Shreve; P C Chiao; H D Humes; M Schwaiger; M D Gross
Journal:  J Nucl Med       Date:  1995-09       Impact factor: 10.057

View more
  9 in total

1.  Renal oncocytoma on 1-11C acetate positron emission tomography: Case report and literature review.

Authors:  Jabi Shriki; Venkatesh Murthy; Jeffrey Brown
Journal:  Mol Imaging Biol       Date:  2006 Jul-Aug       Impact factor: 3.488

2.  (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.

Authors:  Chieh Lin; Chi-Lai Ho; Shu-Hang Ng; Po-Nan Wang; Yenlin Huang; Yu-Chun Lin; Tzung-Chih Tang; Shu-Fan Tsai; Alain Rahmouni; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-16       Impact factor: 9.236

3.  Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies.

Authors:  Ehab M Kamel; Thomas A McKee; Maria-Lucia Calcagni; Sabine Schmidt; Serge Markl; Sandra Castaldo; Angelika Bischof Delaloye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-22       Impact factor: 9.236

4.  1-[11C]-acetate PET imaging in head and neck cancer--a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning.

Authors:  Aijun Sun; Jens Sörensen; Mikael Karlsson; Ingela Turesson; Bengt Langström; Per Nilsson; Lena Cederblad; Jan Bertling; Katrine Riklund; Silvia Johansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

Review 5.  Application of metabolic PET imaging in radiation oncology.

Authors:  Aizhi Zhu; David M Marcus; Hui-Kuo G Shu; Hyunsuk Shim
Journal:  Radiat Res       Date:  2012-02-17       Impact factor: 2.841

6.  [1-(11)C]acetate uptake is not increased in renal cell carcinoma.

Authors:  J Kotzerke; C Linné; M Meinhardt; J Steinbach; M Wirth; G Baretton; N Abolmaali; B Beuthien-Baumann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-30       Impact factor: 9.236

Review 7.  The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors.

Authors:  Laura M Deford-Watts; Akiva Mintz; Steven J Kridel
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

8.  [¹¹C]acetate PET/CT visualizes skeletal muscle exercise participation, impaired function, and recovery after hip arthroplasty; first results.

Authors:  Franz Buchegger; Osman Ratib; Jean-Pierre Willi; Charles Steiner; Yann Seimbille; Habib Zaidi; Véronique Graf; Robin Peter; Maximilien Jung
Journal:  Mol Imaging Biol       Date:  2010-08-31       Impact factor: 3.488

9.  Clinical importance of [18F]fluorodeoxyglucose positron emission tomography/computed tomography in the management of patients with bronchoalveolar carcinoma: Role in the detection of recurrence.

Authors:  Evangelia Skoura; Ioannis E Datseris; Dimitrios Exarhos; Sophia Chatziioannou; Georgios Oikonomopoulos; Alexandros Samartzis; Chariklia Giannopoulou; Konstantinos N Syrigos
Journal:  Oncol Lett       Date:  2013-03-14       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.